David R Holmes 1 , Shephal K Doshi 2 , Saibal Kar 3 , Matthew J Price 4 , Jose M Sanchez 5 , Horst Sievert 6 , Miguel Valderrabano 7 , Vivek Y Reddy 8
Jun 23 2015
Journal of the American College of Cardiology
appendage occlusion, long-term warfarin, stroke prevention, thromboembolism, warfarin alternative
The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continued evaluation.